Thompson Davis & Co’s Vivani Medical VANI Stock Holding History

Thompson Davis & Co’s Portfolio VANI Stock Details VANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10	Closed	-$1K	–	1174
2016 Q1	$1K	Hold	10	–	–	﹤0.01%	1041
2015 Q4	$1K	Buy	+10	New	+$1.46K	﹤0.01%	1099
2015 Q3	–	Sell	-109	Closed	-$36K	–	1244
2015 Q2	$36K	Buy	+109	New	+$35K	0.04%	383

Other funds holding VANI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VDBMI

Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Thompson Davis & Co's VANI Position: Q2 2016 in Review

Thompson Davis & Co sold out of Vivani Medical (VANI) in Q2 2016, closing a stake of 10 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in VANI in Q2 2015 and held it in 3 quarters. The position peaked at $36K in Q2 2015. 57 funds tracked by Wall St. Rank hold VANI as of Q2 2016.

Thompson Davis & Co reported no remaining Vivani Medical position as of Q2 2016 after selling out during the quarter.
Thompson Davis & Co sold 10 Vivani Medical shares in Q2 2016, an estimated $1K.
Thompson Davis & Co first reported a position in Vivani Medical in Q2 2015 and held it in 3 quarters.
Thompson Davis & Co's Vivani Medical position peaked at $36K in Q2 2015.
57 funds tracked by Wall St. Rank held Vivani Medical as of Q2 2016.

Based on Thompson Davis & Co's 13F filing for Q2 2016, filed 9 Aug 2016.